Efficacy of mesoglycan treatment in patients with lower limb ischemia. Preliminary results of a new therapeutic protocol;Efficacia del trattamento con mesoglicano in pazienti con ischemia relativa degli arti inferiori. Risultati preliminari di un nuovo protocollo terapeutico

Minerva Cardioangiologica

Volumn 45, Issue 7-8, 1997, Pages 383-392

  Raso, A M ^a   Maggio, D ^a   Trogolo, M ^a   Rispoli, P ^a   Sandrone, N ^a   Pezzuto, D ^a   Bellan, A ^a   Melloni, C D ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Glycosaminoglycans; Ischemia, therapy

Indexed keywords

MESOGLYCAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; FEMALE; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; HUMAN; LEG ISCHEMIA; MALE; PARTIAL THROMBOPLASTIN TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CLINICAL PROTOCOLS; FEMALE; GLYCOSAMINOGLYCANS; HUMANS; ISCHEMIA; LEG; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0031457646     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Criqui MD Peripheral arterial disease and subsequent cardiovascular mortality. Circulation 1990;82: 2246-7.
2. Criqui MD, Langer RD, Franek A, Feigelson HS, Klauber MR, McKann et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381-6.
3. Green RM, Mc Namara. The effects of pentoxyphilline on patients with intermittent claudication. J Vasc Surg 1988;7:356-62.
4. Coffman JD. Vasodilator drugs in peripheral vascular disease. N Engl J Med 1979;300:713-7.
5. Antiplatelet Trialist Collaboration. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various cathegories of patients. Br Med J 1994;308:81-100.
6. Janzon L, Bergqvist D, Boberg J, Boberg M, Erikkson J, Lingarde F et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J Int Med 1990;227:301-8.
7. Sheffler P, Rieger H. Therapeutic efficacy of intravenously applied prostaglandin. Vasa 1989;28(Suppl): 19-25.
8. Nakashima Y, Segawa J, Kawashima T, Fukuchi Y, Kuroiwa A. Chronic arterial occlusion with PGE - Resistant skin lesions treated by glycosaminoglycan compound - Case reports Angiology 1990;41(9):731-6.
9. Vane JR, Anngard EE, Botting RM. Regulatory functions of vascular endothelium. N Engl J Med 1990;323;27-36
10. Blajchman MA, Young E, Ofosu FA Effects of unfractionated heparan, dermatan sulphate and low molecular weight heparin on vessel wall permeability in rabbits. Ann NY Acad Sci 1985;454.245-54.
11. Rosemberg RD, Reilly C, Fritze L. Atherogenic regulation of heparin-like molecules. In. Atherosclerosis Ann NY Acad Sci 1985;454:270-8.
12. Ofosu FA, Modi GJ, Smith LM, Cerksus AL, Hirsh J, Blajchman MA Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways. Blood 1984; 64(3) 742-6.
13. Berenson GS, Radhakrishnamurty B, Snnivasan SR, Vijgopal PF, Dalferes ER. Proteoglycans and potential mechanisms related to atherosclerosis. In: Atherosclerosis. Ann NY Acad Sci 1985,454:69-78.
14. Agnelli G, Gianese F. Dermatan sulphate Biological and pharmacological properties, clinical applications In: Goldhaber SZ, editor. Prevention of venous thromboembolism. New York: M. Dekker Inc., 1993.287-313.
15. Andreozzi SM, Signorelli S, Lo Duca S. Minacapelli C, Amico-Roxas MT, Minardo G et al Effects of mesoglycan sulfate on the arterial elastic module. Angiology 1987;38(8):593-600.
16. Cugnasca M, Ghilardi G, Pecis C, Odero A, Kunkl E. Medical treatment of chronic arteriosclerotic ischemia of the lower limbs with mesoglycan. Atherosclerosis Cardiovasc Dis 1987;3:951-5
17. Auteri A, Celasco G, Gasparro MG, Verzuri MS, Artale F, Bandiera G et al. I glicosaminoglicani nella terapia delle arteriopatie obliteranti periferiche. G It Angiol 1991;11:24-30.
18. Forconi S, Battistini N, Guerrini M, Passero SG. A randomized, ASA-controlled trial of mesoglycan in secondary prevention after cerebral ischemic events. Cerehrovasc Dis 1995;5:334-41.
19. Restori G, Boiardi L, Mari S, Barbagallo M, Passeri M. Glycosaminoglycans administration (heparan-sulphate, dermatan-sulphate and their combinations 50:50) and reduction of atherosclerosis progression rate in rabbits with a diet-induced hypercholesterolemia. Atherosclerosis Cardiovasc Dis 1989;4:971-5
20. Laurora G, Cesarone MR, De Sanctis C, Incandela F, Belcaro G. Delayed arteriosclerosis progression in high risk subjects treated with mesoglycan. Evaluation of intima-media thickness. J Cardiovasc Surg 1990;34 313-8.
21. Tesi M, Bronchi GF, Carini A, Mirchioni R. Trattamento con mesoglicano solfato nell'arteriopatia aterosclerotica Effetto della somministrazione per via venosa. Riv Farmacol Terapia 1984,15:55-8.
22. De Donato G, De Nicola P, Meucci E. Valulazione strumentale degli effetti del mesoglicano in pazienti arteriopatici (Stadio II di Fontaine) in uno studio in doppio cieco verso placebo Farmaci Terapia 1991, 8:84-8.
23. Davì G, Avellone G, Pinto A, Strano A. Effetti della somministrazione a lungo termine di mesoglicano in pazienti con arteriopatia obliterante degli arti inferiori. Atti del 14th World Congress International Union of Angiology, 1986.
24. Allegra C, Arpaia MR, Del Guercio R, Leonardo G, Mari A, Moschetti B et al. Mesoglicano e malattia arteriosclerotica. Contributo clinico-sperimentale. Minerva Angiol 1987,12(1):15-8.
25. Castriotta G, Ambroso GA. Il mesoglicano nelle arteriopatie ostruttive degli arti inferiori. Minerva Angiol 1989,14(6):43-9.
26. Bettini R, Masciadra M, Tamborini M, Paganini E, Marrapodi E. Studio clinico-strumentale sull'efficacia del mesoglicano in pazienti affetti da artenopatia obliterante degli arti inferiori. Farmaci 1990;14(6): 191-6.
27. Vittoria A, Messa GL, Frigerio C, Celasco G, Auteri A. Effect of single dose of mesoglycan on the human fibrinolytic system and the profibrinolytic action of nine daily doses. Int J Tissue Reaction 1988;4:261-6.
28. Caimi G, Romandini S, Lo Presti R, Serra A, Montana M, Francavilla G et al Erythrocite membrane fluidity during mesoglycan treatment. Clin Hemorheol 1992;12:449-53.
29. Tanganelli P, Bianciardi G, Carducci A, Palummo N, Simoes C, Tarabochia B et al. Updating on the in vivo and in vitro effects of heparin and other glycosaminoglycans (mesoglycan) on arterial endothelium: a morphometrical study Int J Tissue Reaction 1992,14(3),149-53
30. Velussi M, Cernigoi AM, Dapas F, De Monte, Viezzoli L, Caffau C. Effetto del trattamento a lungo termine con mesoglicano o pentossifillina nella microangiopatia diabetica. G Ital Angiol 1995;15(1): 61-8.
31. Ansell JE, Price JM, Shah S, Beckner M. Heparin induced thrombocytopenia. What is its real frequency? Chest 1985;88;878-86.